Zhuo-ming Li
Guangzhou, 510006, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Endothelial PARP1 orchestrates endothelial-to-mesenchymal transition via the PARylation of FHL2 in ischaemic heart failure.
Journal: Acta pharmacologica Sinica
Published: December 09, 2025
Histone methyltransferase G9a drives vascular smooth muscle cell proliferation and intimal hyperplasia in mice.
Journal: Acta pharmacologica Sinica
Published: June 16, 2025
Cytosolic DNA initiates a vicious circle of aging-related endothelial inflammation and mitochondrial dysfunction via STING: the inhibitory effect of Cilostazol.
Journal: Acta pharmacologica Sinica
Published: December 19, 2023
Disturbance of Fatty Acid Metabolism Promoted Vascular Endothelial Cell Senescence via Acetyl-CoA-Induced Protein Acetylation Modification.
Journal: Oxidative medicine and cellular longevity
Published: April 02, 2022
Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives.
Journal: Acta pharmacologica Sinica
Published: May 15, 2020
PARP1 interacts with HMGB1 and promotes its nuclear export in pathological myocardial hypertrophy.
Journal: Acta pharmacologica Sinica
Published: February 03, 2018
Salvia miltiorrhizaBurge (Danshen): a golden herbal medicine in cardiovascular therapeutics.
Journal: Acta pharmacologica Sinica
Published: October 29, 2017
C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling.
Journal: Acta pharmacologica Sinica
Published: November 30, 2016
Synthesis of the novel PARP-1 inhibitor AG-690/11026014 and its protective effects on angiotensin II-induced mouse cardiac remodeling.
Journal: Acta pharmacologica Sinica
Published: September 26, 2016
Showing 1-9 of 9
Last Updated: 09/26/2026